Thus, targeting gut TGR5, either directly with selective agonists or indirectly via microbiome modulation, holds considerable promise as a therapeutic strategy for obesity and related metabolic disorders. This evidence concerns the gene GPBAR1 and obesity due to melanocortin 4 receptor deficiency.